×
ADVERTISEMENT

FEBRUARY 2, 2024

Biogen Pulls the Plug on Alzheimer’s Drug Aducanumab

By SPC Staff

Biogen announced on Jan. 31 that it would abandon the development and commercialization of aducanumab (Aduhelm), its controversial Alzheimer’s disease (AD) drug, citing the need to shift resources to other treatments for the brain disorder.